CMAB Biopharma
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.
Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.
Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 165 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.
At CMAB biopharma, we provide expertise and experience in process and analytical development, drug substance (DS) and drug product (DP) cGMP manufacturing. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer, which is used for protein characterisation. Our four parallel upstream suites offer flexible cGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. CMAB is currently installing a fully automated aseptic fill / finish line along with a lyophiliser, which will be capable of producing commercial quantities of DP in early 2020. Finally, we can also provide our clients with lot release testing and stability studies.
Our operational protocols and quality standards comply with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce cGMP material for global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.
To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com or write to us at hello@cmabbio.com. We look forward to hearing from you.
